I'rom Group Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Full Year Ended March 31, 2017; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2018
May 11, 2017
Share
I'rom Group Co., Ltd. reported consolidated and non-consolidated earnings results for the full year ended March 31, 2017. For the year, on consolidated basis, the company reported net sales of JPY 4,890 million compared to JPY 4,114 million a year ago. Operating income was JPY 212 million compared to operating loss of JPY 480 million a year ago. Ordinary income was JPY 272 million compared to ordinary loss of JPY 807 million a year ago. Net income attributable to owners of parent was of JPY 204 million or JPY 18.72 per diluted share compared to net loss attributable to owners of parent of JPY 868 million a year ago. Return on equity was 5.1% compared to negative return on equity was of 21.5% a year ago. Cash used in operating activities were of JPY 826 million compared to JPY 271 million a year ago.
On non-consolidated basis, the company reported net sales of JPY 731 million compared to JPY 766 million a year ago. Operating income was JPY 50 million compared to JPY 35 million a year ago. Ordinary income was JPY 89 million compared to ordinary loss of JPY 334 million a year ago. Net income was of JPY 105 million or JPY 9.63 per diluted share compared to net loss of JPY 339 million a year ago.
The company provided consolidated earnings guidance for the fiscal year ending March 31, 2018. For the year, on consolidated basis, the company expects net sales of JPY 9,500 million, operating income of JPY 800 million, ordinary income was JPY 800 million and net income attributable to owners of parent was of JPY 500 million of JPY 45.96 per share.
I'rom Group Co.,Ltd. is engaged in medical fields such as regenerative medicine and gene discovery. The Company operates through four business segments. The SMO segment provides support services for contracting or substituting a part of the work related to conducting clinical trials from the conducting medical institution. The CRO segment provides all or part of clinical trial operations from pharmaceutical companies and others. The Advanced Medicinal Treatment segment is engaged in the development of gene therapy products, the development, manufacture and sale of products in the field of regenerative medicine based on iPS cells related technologies, as well as the provision of contract manufacture services. The Medical Support segment provides general and comprehensive support for medical business management, such as setting up and renting clinic malls, selling products and related services. The Company also provides business utilizing IT infrastructure.
I'rom Group Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Full Year Ended March 31, 2017; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2018